News

VALLEY FORGE, Pa.--(BW HealthWire)--April 10, 2001--AmeriSource Health Corporation (NYSE:AAS) today announced that it plans to release its Second Quarter FY2001 results on Thursday, April 26, 2001 prior to the opening of the New York Stock Exchange.

The Company will host a conference call to discuss the results at 1:00 pm Eastern Daylight Time on April 26, 2001. Participating in the conference call will be:

The dial in numbers for the live call will be as follows:

In order to ensure the widest distribution possible, the Company will be broadcasting the conference call over the Internet. The call will be accessible through Street Events, www.streetevents.com, and also through AmeriSource's web site, www.amerisource.com . Users are encouraged to log on to the webcast approximately 15 minutes in advance of the scheduled start time of the call.

Following the live call, replays will be made available on the Internet and via telephone. A replay of the webcast will be posted on www.amerisource.com approximately two hours after the completion of the call and will remain available for thirty days. To access the telephone replay, from within the US dial 800-475-6701. From outside the US, dial 320-365-3844. The access code is 580955.

The telephone replay will be available from 4:30 p.m. EST on 4/26/01 to 11:59 p.m. on 5/3/01.

About AmeriSource

AmeriSource Health Corporation, with more than $13 billion in annualized operating revenue, is a leading distributor of pharmaceutical and related healthcare products and services, and the industry's largest provider of pharmaceuticals to acute care/health systems customers.

Headquartered in Valley Forge, PA, the Company serves its base of about 15,000 customer accounts through a national network of 22 strategically located drug distribution facilities. For news and additional information about the company, visit its web site at www.amerisource.com.

Certain information contained in this press release includes forward-looking statements (as defined in Section 27A of the Securities Act and Section 21E of the Exchange Act) that reflect the Company's current views with respect to future events and financial performance. Certain factors such as competitive pressures, success of restructuring or systems initiatives, market interest rates, regulatory changes, continued industry consolidation, changes in customer mix, changes in pharmaceutical manufacturers' pricing and distribution policies, changes in U.S. government policies, customer insolvencies, the loss of one or more key customer or supplier relationships and other matters contained in the Company's 10-K for fiscal year 2000 and other public documents could cause actual results to differ materially from those in the forward-looking statements. The company assumes no obligation to update the matters discussed in this press release.

Additional Information About The Merger

In connection with their proposed merger, AmeriSource and Bergen Brunswig will file a joint proxy statement/prospectus with the Securities and Exchange Commission. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus (when available) and other documents filed by AmeriSource and Bergen Brunswig at the Securities and Exchange Commission's web site at www.sec.gov. The joint proxy statement/prospectus and such other documents may also be obtained for free from AmeriSource by directing such request to AmeriSource Health Corporation, General Counsel, 1300 Morris Drive, Suite 100, Chesterbrook, Pennsylvania 19087-5594, Telephone: (610) 727-7000. AmeriSource's directors, executive officers and other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed merger. Information concerning AmeriSource's participants in the solicitation is set forth in AmeriSource's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2001.